Pfizer and Celgene, as well as Osage University Partners and others, have backed a $38m series A round to help launch Arrakis Therapeutics.

Pfizer and Celgene, as well as Osage University Partners and others, have backed a $38m series A round to help launch Arrakis Therapeutics.

Malin Corporation returned to back Xenex, which will use the cash to drive international expansion, recruitment, product development and scientific research.

Apollo Therapeutics, the commercialisation fund backed by Imperial College London, UCL and Cambridge University, has approved its first four drug discovery projects.